These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 34472667)

  • 1. Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer.
    Barroso-Sousa R; Vaz-Luis I; Di Meglio A; Hu J; Li T; Rees R; Sinclair N; Milisits L; Leone JP; Constantine M; Faggen M; Briccetti F; Block C; Partridge A; Burstein H; Waks AG; Tayob N; Trippa L; Tolaney SM; Hassett MJ; Winer EP; Lin NU
    Oncologist; 2021 Nov; 26(11):927-933. PubMed ID: 34472667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients.
    de Castro Baccarin AL; Irene MN; de Iracema Gomes Cubero D; Luz AS; Castro SN; Sordi R; Móz LES; Del Giglio A
    Support Care Cancer; 2019 Mar; 27(3):927-931. PubMed ID: 30069696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy.
    Parinyanitikul N; Tanpipattanakul W; Poovorawan N; Rattananupong T; Laoitthi P; Sithidetphaiboon P; Thanasanvimon S; Sriuranpong V
    Support Care Cancer; 2018 Jul; 26(7):2471-2477. PubMed ID: 29435713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Premedication strategy for weekly paclitaxel.
    Quock J; Dea G; Tanaka M; Gandara D; Lara P; Lau D
    Cancer Invest; 2002; 20(5-6):666-72. PubMed ID: 12197222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions.
    Sasada S; Hirashima T; Nakamura Y; Takimoto T; Furukawa M; Kobayashi M; Nitta T; Matsui K; Kawase I
    Int J Clin Oncol; 2007 Aug; 12(4):274-8. PubMed ID: 17701006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do Steroids Matter? A Retrospective Review of Premedication for Taxane Chemotherapy and Hypersensitivity Reactions.
    Lansinger OM; Biedermann S; He Z; Colevas AD
    J Clin Oncol; 2021 Nov; 39(32):3583-3590. PubMed ID: 34357780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranitidine and the incidence of hypersensitivity reactions to paclitaxel: A retrospective cohort study.
    Haine AI; Notenboom CMAW; Tan LVP; Ruiter R; van der Deure WM
    Pharmacol Res Perspect; 2022 Aug; 10(4):e00985. PubMed ID: 35811355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, Controlled Trial of Dexamethasone Versus Dexamethasone Plus Hydrocortisone as Prophylaxis for Hypersensitivity Reactions Due to Paclitaxel Treatment for Gynecologic Cancer.
    Jeerakornpassawat D; Suprasert P
    Int J Gynecol Cancer; 2017 Oct; 27(8):1794-1801. PubMed ID: 28704328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is a low dose of dexamethasone sufficient to prevent paclitaxel-related hypersensitivity reactions? A retrospective study in patients with gynecologic malignancy.
    Xiao D; Yang Z; Shi Y; Yang W; Zhang Y
    Expert Rev Clin Pharmacol; 2024; 17(5-6):525-532. PubMed ID: 38652518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of the effects of oral and intravenous dexamethasone premedication in the prevention of paclitaxel-induced allergic reactions.
    Chen FC; Wang LH; Zheng XY; Zhang XM; Zhang J; Li LJ
    Oncotarget; 2017 Mar; 8(12):19236-19243. PubMed ID: 27911278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of institutional interventions on the rate of paclitaxel hypersensitivity reactions.
    Jao ME; Indorf AL; Segal EM; Miske A; Eaton KD; Marsolini T; Ghuman S
    J Oncol Pharm Pract; 2024 Jan; 30(1):105-111. PubMed ID: 37021579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-sensitivity between taxanes in patients with breast cancer.
    Sánchez-Muñoz A; Jiménez B; García-Tapiador A; Romero-García G; Medina L; Navarro V; González-Sánchez LA; Alba E
    Clin Transl Oncol; 2011 Dec; 13(12):904-6. PubMed ID: 22126735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histamine-2 (H
    Foreman E; Polwart C; Walker A; Chambers P
    Br J Clin Pharmacol; 2022 Sep; 88(9):4191-4198. PubMed ID: 35470452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The added value of H
    Cox JM; van Doorn L; Malmberg R; Oomen-de Hoop E; Bosch TM; van den Bemt PMLA; Boere IA; Jager A; Mathijssen RHJ; van Leeuwen RWF
    Br J Cancer; 2021 May; 124(10):1647-1652. PubMed ID: 33762718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose dexamethasone paclitaxel premedication.
    Micha JP; Rettenmaier MA; Dillman R; Fraser P; Birk C; Brown JV
    Gynecol Oncol; 1998 May; 69(2):122-4. PubMed ID: 9600818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous versus oral dexamethasone premedication in preventing Paclitaxel infusion hypersensitivity reactions in gynecological malignancies.
    O'Cathail SM; Shaboodien R; Mahmoud S; Carty K; O'Sullivan P; Blagden S; Gabra H; Whear S; Kwon JS; Agarwal R
    Int J Gynecol Cancer; 2013 Sep; 23(7):1318-25. PubMed ID: 23907557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments.
    Feldweg AM; Lee CW; Matulonis UA; Castells M
    Gynecol Oncol; 2005 Mar; 96(3):824-9. PubMed ID: 15721432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Premedication Protocols to Prevent Hypersensitivity Reactions to Chemotherapy: a Literature Review.
    ALMuhizi F; De Las Vecillas Sanchez L; Gilbert L; Copaescu AM; Isabwe GAC
    Clin Rev Allergy Immunol; 2022 Jun; 62(3):534-547. PubMed ID: 35258842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful re-treatment with taxol after major hypersensitivity reactions.
    Peereboom DM; Donehower RC; Eisenhauer EA; McGuire WP; Onetto N; Hubbard JL; Piccart M; Gianni L; Rowinsky EK
    J Clin Oncol; 1993 May; 11(5):885-90. PubMed ID: 8098057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the efficacy of a premedication regimen including high-dose cetirizine in reduction of hypersensitivity reactions to paclitaxel: A retrospective cohort study.
    Hutchinson A; Weaver K; Gunaratnam B; Volz L; Ingles L; Figg L
    J Oncol Pharm Pract; 2024 Jul; ():10781552241263832. PubMed ID: 39042936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.